Imago BioSciences   Report issue

For profit Phase 1 Phase 2
Founded: San Carlos CA United States (2012)

Organization Overview

First Clinical Trial
2016
NCT02842827
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Imago BioSciences,Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

img-7289 (5 trials)

Drugs in Phase 1 Trials (1)

tretinoin (Retin-A) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Myelodysplastic Syndromes (Phase 1)

Polycythemia (Phase 2)

Polycythemia Vera (Phase 2)

Primary Myelofibrosis (Phase 1)

Thrombocythemia, Essential (Phase 2)

Thrombocytosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 2